{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:18:40Z","timestamp":1790205520978,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejca.2026.116784","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T23:57:11Z","timestamp":1778025431000},"page":"116784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The case for tumour-agnostic reimbursement of dual immunotherapy"],"prefix":"10.1016","volume":"241","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-6837","authenticated-orcid":false,"given":"Vivek","family":"Subbiah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116784_bib1","unstructured":"The Hon Mark Butler MP. Immunotherapy for patients with advanced cancers. Https:\/\/WwwHealthGovAu\/Ministers\/the-Hon-Mark-Butler-Mp\/Media\/Immunotherapy-for-Patients-with-Advanced-Cancers 2025."},{"key":"10.1016\/j.ejca.2026.116784_bib2","article-title":"Doorn-Khosrovani. Bypassing the evidence pathway: world-first tumour-agnostic reimbursement for dual immunotherapy","author":"van Waalwijk van","year":"2026","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116784_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn6911","article-title":"For insights into the real world, consider real-world data","volume":"14","author":"Raoof","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejca.2026.116784_bib4","first-page":"261","article-title":"The burden of rare cancers in the United States","volume":"67","author":"DeSantis","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2026.116784_bib5","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-100051","article-title":"Designing clinical trials for patients with rare cancers: connecting the zebras","volume":"45","author":"Subbiah","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ejca.2026.116784_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002990","article-title":"Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)","volume":"9","author":"Wagner","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116784_bib7","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2303383","article-title":"Atezolizumab for advanced alveolar soft part sarcoma","volume":"389","author":"Chen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116784_bib8","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1002\/cncr.33591","article-title":"A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort","volume":"127","author":"Patel","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2026.116784_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008872","article-title":"Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden","volume":"12","author":"Schenker","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116784_bib10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1158\/1078-0432.CCR-23-2293","article-title":"A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia","volume":"30","author":"Patel","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116784_bib11","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/cac2.70020","article-title":"A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort","volume":"45","author":"Chae","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.ejca.2026.116784_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009074","article-title":"Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort","volume":"12","author":"Patel","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116784_bib13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1158\/1078-0432.CCR-21-2182","article-title":"A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609)","volume":"28","author":"Adams","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116784_bib14","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2026.116784_bib15","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116784_bib16","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116784_bib17","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.annonc.2020.07.002","article-title":"The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) \u226510: a decision centered on empowering patients and their physicians","volume":"31","author":"Subbiah","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116784_bib18","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2026.116784_bib19","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1470-2045(22)00392-8","article-title":"Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial","volume":"23","author":"Somaiah","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116784_bib20","doi-asserted-by":"crossref","first-page":"11503","DOI":"10.1200\/JCO.2023.41.16_suppl.11503","article-title":"A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902)","volume":"41","author":"Grilley-Olson","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116784_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012805","article-title":"DART\/SWOG\/NCI phase II anti-CTLA-4\/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix","volume":"14","author":"Chae","year":"2026","journal-title":"J Immunother Cancer"},{"issue":"Number 16_","key":"10.1016\/j.ejca.2026.116784_bib22","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1200\/JCO.2023.41.16_suppl.5517","article-title":"A phase II basket trial of dual anti\u2013CTLA-4 and anti\u2013PD-1 blockade in rare tumors (DART) SWOG S1609: The vulvar cancers","volume":"41","author":"Chae","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116784_bib23","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2326-6066.CIR-18-0121","article-title":"Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade","volume":"6","author":"Galanina","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ejca.2026.116784_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005620","article-title":"Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab","volume":"10","author":"Berger","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116784_bib25","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/1878-0261.12748","article-title":"Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy","volume":"14","author":"Pham","year":"2020","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ejca.2026.116784_bib26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41591-019-0749-z","article-title":"The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research","volume":"26","author":"Painter","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116784_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13073-020-00753-2","article-title":"Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing","volume":"12","author":"Boichard","year":"2020","journal-title":"Genome Med"},{"issue":"2","key":"10.1016\/j.ejca.2026.116784_bib28","doi-asserted-by":"crossref","DOI":"10.1200\/OA-25-00110","article-title":"Outcomes of patients with rare cancers treated with combination immune checkpoint inhibitors with and without prior anti-PD-1\/L1 Exposure (NCI\/SWOG S1609)","author":"Othus","year":"2025","journal-title":"JCO Oncol Adv"},{"key":"10.1016\/j.ejca.2026.116784_bib29","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-01546","article-title":"Efficacy and safety of ultra-low-dose immunotherapy in relapsed refractory solid tumors: phase iii superiority randomized trial (DELII)","author":"Noronha","year":"2026","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926005654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926005654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:26:24Z","timestamp":1780359984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926005654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":29,"alternative-id":["S0959804926005654"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116784","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The case for tumour-agnostic reimbursement of dual immunotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116784","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116785","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116784"}}